You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

~ Buy the NEUPRO (rotigotine) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR NEUPRO


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for NEUPRO

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00292227 ↗ Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease Completed UCB Pharma Phase 1 2006-01-01 The purpose of this trial is to assess whether rotigotine has an effect on the electrical activity of the heart. Moxifloxacin infusion is used as positive control to assess assay sensitivity.
NCT00296192 ↗ Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson Symptoms Completed UCB Pharma Phase 2 2006-02-01 The objective of this trial is to evaluate safety and efficacy of rotigotine nasal spray (SPM 952) in a single dose application scheme. Subjects will undergo a 2 - 28 days screening period in which eligibility criteria will be checked. Subjects will then be hospitalized for one night. In the morning of the next day, subjects will be randomly assigned either to rotigotine or placebo nasal spray and will then receive a single dose of trial medication. Safety assessments after application include adverse events, 12-lead electrocardiograms, blood pressure and heart rate assessments, and laboratory checks. Efficacy will be assessed by application of motor examination scores. The first subject is planned to be enrolled in February 2006. The last subject is planned to be enrolled in May 2006. Last subject out is expected for August 2006.
NCT00464737 ↗ The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults. Completed UCB Pharma Phase 2 2007-03-01 This trial is to investigate the efficacy and safety of rotigotine as compared to placebo in reducing signs and symptoms of fibromyalgia syndrome. The effects of rotigotine on pain, sleep, general activity, mood, and quality of life, and the use of rescue medication to treat pain will be assessed.
NCT00474058 ↗ Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine Completed UCB Pharma Phase 3 2007-05-01 The objective of this trial is to assess the effects of transdermal rotigotine on the control of early morning motor function and sleep disorders compared to placebo in subjects with idiopathic Parkinsons´s disease. In addition, effects of rotigotine on specific nocturnal and non-motor symptoms of Parkinson´s disease will be evaluated.
NCT00505687 ↗ An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease Completed UCB Pharma Phase 3 2005-02-01 The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of rotigotine in subjects with idiopathic PD.
NCT00522379 ↗ Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch Completed UCB Pharma Phase 3 2007-07-01 The purpose of this study is to show Rotigotine dose response at four doses of Rotigotine used with L-dopa in treating advanced stage Parkinson's disease.
NCT00593606 ↗ Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine Completed UCB Pharma Phase 3 2007-07-01 This is a Phase 3b, open-label, multicenter trial to assess the safety and tolerability of switching from ropinirole therapy to the rotigotine transdermal system and its effect on symptoms in subjects with idiopathic Parkinson's disease
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for NEUPRO

Condition Name

Condition Name for NEUPRO
Intervention Trials
Parkinson's Disease 13
Restless Legs Syndrome 5
Parkinson Disease 4
Healthy 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for NEUPRO
Intervention Trials
Parkinson Disease 23
Syndrome 7
Psychomotor Agitation 6
Restless Legs Syndrome 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for NEUPRO

Trials by Country

Trials by Country for NEUPRO
Location Trials
United States 144
Germany 12
Canada 9
Italy 9
India 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for NEUPRO
Location Trials
Florida 12
California 10
Texas 8
New York 7
North Carolina 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for NEUPRO

Clinical Trial Phase

Clinical Trial Phase for NEUPRO
Clinical Trial Phase Trials
Phase 4 6
Phase 3 11
Phase 2 7
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for NEUPRO
Clinical Trial Phase Trials
Completed 31
Recruiting 2
Terminated 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for NEUPRO

Sponsor Name

Sponsor Name for NEUPRO
Sponsor Trials
UCB Pharma 17
UCB BIOSCIENCES GmbH 7
Luye Pharma Group Ltd. 4
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for NEUPRO
Sponsor Trials
Industry 35
Other 15
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.